Zhenhao Qi

863 total citations
18 papers, 548 citations indexed

About

Zhenhao Qi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Zhenhao Qi has authored 18 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Zhenhao Qi's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Zhenhao Qi is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Zhenhao Qi collaborates with scholars based in United States, Japan and Taiwan. Zhenhao Qi's co-authors include Mark R. O’Brian, Iqbal Hamza, Natalie D. King, John Cogswell, Maurice M. Morelock, Martin S. Kluger, Adedayo Hanidu, Todd Jensen, Revati J. Tatake and Jordan S. Pober and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Zhenhao Qi

18 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenhao Qi United States 12 279 119 109 79 74 18 548
Ji-Yun Lee South Korea 13 290 1.0× 65 0.5× 87 0.8× 36 0.5× 39 0.5× 34 551
Yeqing Yuan China 18 434 1.6× 164 1.4× 48 0.4× 154 1.9× 39 0.5× 38 921
Yosuke Miyachi Japan 13 178 0.6× 81 0.7× 12 0.1× 42 0.5× 153 2.1× 41 617
Anjali Nandal United States 7 253 0.9× 51 0.4× 23 0.2× 78 1.0× 34 0.5× 9 607
Sergey Pryshchep United States 13 167 0.6× 96 0.8× 19 0.2× 17 0.2× 36 0.5× 15 669
Ursula Denk Austria 11 134 0.5× 61 0.5× 73 0.7× 50 0.6× 51 0.7× 14 740
Jianying Liang China 14 300 1.1× 23 0.2× 16 0.1× 33 0.4× 115 1.6× 41 628
Sharon Dingle United States 7 358 1.3× 70 0.6× 27 0.2× 405 5.1× 57 0.8× 11 797
Kiyoshi Sekiguchi Japan 9 206 0.7× 65 0.5× 38 0.3× 39 0.5× 42 0.6× 19 507
Shanshan Duan China 11 607 2.2× 207 1.7× 16 0.1× 30 0.4× 84 1.1× 27 801

Countries citing papers authored by Zhenhao Qi

Since Specialization
Citations

This map shows the geographic impact of Zhenhao Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenhao Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenhao Qi more than expected).

Fields of papers citing papers by Zhenhao Qi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenhao Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenhao Qi. The network helps show where Zhenhao Qi may publish in the future.

Co-authorship network of co-authors of Zhenhao Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenhao Qi. A scholar is included among the top collaborators of Zhenhao Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenhao Qi. Zhenhao Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
Steuer, Conor, Hidetoshi Hayashi, Wu‐Chou Su, et al.. (2022). Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.. Journal of Clinical Oncology. 40(16_suppl). 9017–9017. 21 indexed citations
4.
Jänne, Pasi A., Christina S. Baik, Wu‐Chou Su, et al.. (2021). Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). 9007–9007. 20 indexed citations
5.
Yu, Helena A., Christina S. Baik, Kathryn A. Gold, et al.. (2021). OA03.04 Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC. Journal of Thoracic Oncology. 16(3). S107–S107. 1 indexed citations
6.
Yu, Helena A., Christina S. Baik, Kathryn A. Gold, et al.. (2020). LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC. Annals of Oncology. 31. S1189–S1190. 16 indexed citations
7.
Qi, Zhenhao, Lisu Wang, Keyur Desai, et al.. (2019). Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin–Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform. Journal of Molecular Diagnostics. 21(5). 796–807. 17 indexed citations
8.
Szabó, Péter M., George Lee, Scott Ely, et al.. (2019). CD8+ T cells in tumor parenchyma and stroma by image analysis (IA) and gene expression profiling (GEP): Potential biomarkers for immuno-oncology (I-O) therapy.. Journal of Clinical Oncology. 37(15_suppl). 2594–2594. 4 indexed citations
9.
Szabó, Péter M., Zhenhao Qi, Kim E. Zerba, et al.. (2019). Association of an inflammatory gene signature with CD8 expression by immunohistochemistry (IHC) in multiple tumor types.. Journal of Clinical Oncology. 37(15_suppl). 2593–2593. 2 indexed citations
10.
Aung, Kyaw, Anthony B. El-Khoueiry, Karen A. Gelmon, et al.. (2018). A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Investigational New Drugs. 36(6). 1026–1036. 32 indexed citations
11.
El-Khoueiry, Anthony B., Jayesh Desai, Swaminathan P. Iyer, et al.. (2018). A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2515–2515. 20 indexed citations
12.
Qi, Zhenhao, Lisu Wang, Aiqing He, Manling Ma-Edmonds, & John Cogswell. (2016). Evaluation and Selection of A Non-PCR Based Technology for Improved Gene Expression Profiling from Clinical Formalin-Fixed, Paraffin-Embedded Samples. Bioanalysis. 8(22). 2305–2316. 4 indexed citations
13.
Huang, Fei, Chang Han, Ann Greer, et al.. (2014). IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines. Molecular Cancer Therapeutics. 14(2). 620–630. 25 indexed citations
14.
Wang, Xi-De, H. David Inzunza, Chang Han, et al.. (2013). Mutations in the Hedgehog Pathway Genes SMO and PTCH1 in Human Gastric Tumors. PLoS ONE. 8(1). e54415–e54415. 32 indexed citations
15.
Clark, Paul, Todd Jensen, Martin S. Kluger, et al.. (2010). MEK5 is Activated by Shear Stress, Activates ERK5 and Induces KLF4 to Modulate TNF Responses in Human Dermal Microvascular Endothelial Cells. Microcirculation. 18(2). 102–117. 62 indexed citations
16.
Qi, Zhenhao & Mark R. O’Brian. (2002). Interaction between the Bacterial Iron Response Regulator and Ferrochelatase Mediates Genetic Control of Heme Biosynthesis. Molecular Cell. 9(1). 155–162. 93 indexed citations
17.
Hamza, Iqbal, Zhenhao Qi, Natalie D. King, & Mark R. O’Brian. (2000). Fur-independent regulation of iron metabolism by Irr in Bradyrhizobium japonicum. Microbiology. 146(3). 669–676. 56 indexed citations
18.
Qi, Zhenhao, Iqbal Hamza, & Mark R. O’Brian. (1999). Heme is an effector molecule for iron-dependent degradation of the bacterial iron response regulator (Irr) protein. Proceedings of the National Academy of Sciences. 96(23). 13056–13061. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ji-Yun Lee Breakdown of academic impact, for papers by Yeqing Yuan Breakdown of academic impact, for papers by Yosuke Miyachi Breakdown of academic impact, for papers by Anjali Nandal Breakdown of academic impact, for papers by Sergey Pryshchep Breakdown of academic impact, for papers by Ursula Denk Breakdown of academic impact, for papers by Jianying Liang Breakdown of academic impact, for papers by Sharon Dingle Breakdown of academic impact, for papers by Kiyoshi Sekiguchi Breakdown of academic impact, for papers by Shanshan Duan
Rankless by CCL
2026